Psychedelics Cybin reaches end of psilocybin analogue clinical trial for depression CYB003 is a molecule developed by the company with rapid onset and a short duration Rowan DunneAugust 3, 2023
News Cybin expands psychedelic facilitator training program EMBARK The program is meant to offer and expand skillful and ethical lessons in the field of psychedelic therapeutics Natalia Buendia CalvilloJuly 12, 2023
Canada PsyCan aims to be ‘go-to’ psychedelics industry organization, receives support from lawmakers The non-profit trade association received a high level of interest from multiple branches of government Rowan DunneNovember 10, 2022
Business Entheon Biomedical hands off DMT clinical study to Cybin Dimethyltryptamine continues to demonstrate tremendous therapeutic potential Rowan DunneJune 14, 2022